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Introduction 
In the past years, the number of different 
biologics for treatment of plaque psoriasis has 
increased considerably. Drugs with new targets 
(IL17A, IL17RA, IL23) have been developed and 
several drugs with the same molecular target are 
available, for example ixekizumab and 
secukinumab, both blocking IL17A. When a 
biologic therapy fails, the question arises whether 
a biologic with the same target or with a different 
target should be given. Although there is data 
available on this issue for TNF-blockers [1, 2], only 
a few studies have addressed this question for 
IL17A-blockers [3-6]. Herein, we present a 
retrospective analysis of patients who were 
switched from secukinumab to ixekizumab with 
an observation of at least 24 weeks. 
 
Case Synopses 
Adult patients with plaque psoriasis treated in the 
dermatology departments of four German 
universities who received ixekizumab after prior 
treatment with secukinumab were identified. Only 
patients who started ixekizumab at least 24 weeks 
prior to data collection were included. Patient 
characteristics were extracted from their medical 
records. Additionally, treatment with secukinumab 
and ixekizumab with regard to dosage, 
concomitant treatment, treatment duration, 
cutaneous efficacy (PASI, primary non-response, 
Abstract 
Switching of biologic agents in treatment of 
plaque psoriasis is a common strategy. Only a few 
studies are available on switching between IL17A-
blockers. In a retrospective study, we identified 22 
psoriasis patients who, after failing secukinumab 
as a first IL17A-blocker received ixekizumab with 
an observation period of at least 24 weeks. At last 
observation 10/22 patients had a good response 
(PASI75 or PASI<3) using ixekizumab therapy. 
None of five patients with primary non-response 
to secukinumab reached a good, durable 
response to ixekizumab. In conclusion, ixekizumab 
appears to be a therapeutic option as a second 
IL17A-blocker in psoriasis patients who did not 
show a primary non-response to secukinumab. 
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secondary non-response), efficacy on psoriatic 
arthritis (PsA), adverse events (AEs), and reason 
for drug discontinuation were assessed. A good 
response was defined as reaching a PASI75 or a 
PASI value <3.0, partial response as reaching a 
PASI50, primary non-response as not reaching a 
PASI50, and secondary non-response as losing a 
PASI50 response. The study was performed 
according to the principles of the Declaration of 
Helsinki and approved by the ethics committees 
of all participating centers [7]. 
A total of 22 patients, among them 6 smokers, 
were identified whose baseline characteristics are 
shown in Table 1. Of these, 16 patients suffered 
from additional psoriatic arthritis (PsA) and 
patients had been pretreated with 4.9±2.6 
systemic therapies before treatment with 
secukinumab, among those 2.4±2.0 biologics. 
Patients had a mean PASI value of 15.9±8.4 at the 
start of secukinumab therapy (Table 1). In 21 
patients secukinumab was given in a dose as 
licensed for plaque psoriasis (with dose escalation 
in 6 patients receiving 300mg every three weeks) 
and in one patient as licensed for psoriasis 
arthritis. Treatment duration with secukinumab 
lasted on average 16.0±7.6 months. The most 
frequent reasons for treatment discontinuation 
were secondary (12/22) and primary non-
response (5/22) of the skin. In three patients 
secukinumab was stopped owing to non-
response of joints and in another two patients 
because of adverse events. Of these 22 patients, 
16 were switched directly from secukinumab to 
ixekizumab whereas 6 patients received at least 
one other systemic therapy in between. 
The mean PASI value at baseline of ixekizumab 
therapy (available in 21 patients) was 12.0±5.5. 
Ixekizumab was given in a dose licensed for 
plaque psoriasis in all cases. Three patients 
received additionally methotrexate, one 
leflunomide, and another patient oral 
prednisolone (for treatment of multiple sclerosis). 
At week 12, 11/21 patients (52.4%) with available 
data reached a good response (PASI 75 response 
or PASI<3). At week 24, eight of 19 patients 
(42.1%) had a good response (prior 
discontinuation (N=1) counting as non-response, 
three patients without data), (Table 1). At last 
observation, 16/22 patients were still on therapy 
with ixekizumab (Figure 1). Of these 16 patients, 
10 patients (62.5%) showed a good response, two 
patients a PASI 50 response and four patients a 
secondary non-response at final observation. All 
these 12 patients showing a good or a partial 
response under ixekizumab therapy had 
experienced at least a partial primary response 
during secukinumab therapy (Figure 1). Among 
the six patients who discontinued ixekizumab, two 
had primary and four secondary non-response to 
ixekizumab. Table 1 gives additional information 
on the respective mean PASI values (as observed) 
at the indicated time points. Adverse events 
during ixekizumab therapy consisted of injection 
site reactions (three patients), one abscess, 
common cold, herpes zoster, and a subtotal 
coronary artery stenosis following stent 
implantation.  
 
Discussion 
In our study at week 12, 52.4% of patients reached 
a good response to ixekizumab as second IL17A-
blocker. This is less compared to three other 
retrospective studies in which patients receiving 
ixekizumab as second IL17A-blocker reached a 
PASI 75 response at week 12 in 71% [5], 81% [4], 
or even 100% [3]. In another retrospective study, 
50% PASI 75 response at week 12 to ixekizumab 
as second IL17A-blocker was comparable to ours’ 
[8]. Until now, to our knowledge, only one study 
reported PASI 75 responses after 24 weeks of 
ixekizumab as second IL17A-blocker, which were 
reached by a higher proportion of patients (80%), 
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Table 1. Demographics and characteristics of patients receiving therapy with ixekizumab after failure to secukinumab 
treatment. 
Baseline characteristics Number / mean±SD 
Gender male n=18 female n=5 
Age (years) 47.4±8.2 (range 35–69) 
BMI 32.8±6.1 (range 23.2–41) 
Age at onset of disease (years) 23.7±10.0 (range 11–56) 
Disease duration (years) 24.0±11.0 (range 3–41) 
Family history of psoriasis 10 pos, 9 neg, 4 unknown 
Psoriatic arthritis 17 pos, 5 neg, 1 uncertain 
Smoking status 7 smoker, 7 ex-smoker, 3 non-smoker, 6 unknown 
Comorbidities obesity n=12, hypertension n= 13, diabetes mellitus n=5, steatosis hepatis n=6 
Number of systemic 
pretreatments 
5.0±2.6 (range 2–10) 
Number of prior biologics 2.4±2.0 (range 0–7) 
Dosage of SECU 
as licensed for plaque psoriasis in 22 patients (dose escalation in the course in 6 
patients: 300mg every 3 weeks), as licensed for PsA in 1 patient 
Dosage of IXE as licensed for plaque psoriasis 
PASI at baseline SECU 15.9±8.4 (range 8.7 to 42) 
Therapy duration of SECU  16.0±7.6 months 
Cause of SECU discontinuation 
4x prim nr skin, 3x nr joints, 12x sec nr skin, 1x nr skin, 2x AEs (one patient with a 
lichenoid reaction and one patient with an urticarial rash) 
Therapies between SECU and IXE 
1 drug in 6 patients (3x certolizumab, 1x etanercept, 1x apremilast, 1x infliximab), 
three drugs in 1 patient (etanercept, infliximab and ustekinumab) 
PASI at baseline IXE (21) * 12.0±5.5 (range 2.0–27.9) 
PASI at weeks 12–16 (21) * 3.7±3.1 (range 0.0–11.7) 
PASI at weeks 24–26 (17) * 5.0±4.7 (range 0.0–13.1) 
PASI at weeks 36–40 (9) * 5.7±5.2 (range 0.0–12.8) 
PASI at weeks 48–52 (10) * 3.0±2.2 (range 0.0–6.4).  
PASI at weeks 60–72 (8) * 9.0±10.1 (range 0.0–31.9) 
Response at weeks 12–16 (21) * 11x PASI 75, 7x PASI 50, 3x prim nr, (1x no data)  
Response at weeks 24–26 (18) * 8x PASI 75, 3x PASI 50, 5x sec nr, 2x prim nr, (3x no data, 1x IXE stopped)  
Response at weeks 36–40 (9) * 4x PASI 75, 2x PASI 50, 3x sec nr, (5x no data, 2x IXE stopped, 6 x EoO) 
Response at weeks 48–52 (10) * 6x PASI 75, 3x PASI 50, 1x sec nr, (1x no data, 4x IXE stopped, 7x EoO)  
Response at weeks 60–72 (8) * 3x PASI 75, 1x PASI 50, 4x sec nr (4x IXE stopped, 10x EoO) 
Concomitant therapies 3x MTX, 1x leflunomide, 1x prednisolone (for multiple sclerosis) 
Therapy duration of IXE (all) 12.4±5.2 months (range 5–20) 
Therapy duration of patients who 
discontinued IXE 
9.8±3.9 months (range 5–15) 
Cause of IXE discontinuation 2x prim nr skin, 4x sec nr skin 
Adverse events to IXE 
3x injection site reaction, 1x abscess (localization unknown), subtotal LAD 
coronary artery stenosis, herpes zoster, common cold 
* SECU was stopped due to 2x prim nr joints, 1x sec nr joints and 2x AE. ** Therapy with ixekizumab was discontinued, Abbreviations: nr non-
response, rp response, prim primary, sec secondary, IXE ixekizumab, SECU secukinumab. 
 
compared to 42.1% in our study [4]. The reasons 
for the reported differences in PASI 75 response 
rates between the studies are not clear but may 
be manifold. Possibly, our patients suffered from 
a more recalcitrant disease. However, the number 
of previous systemic therapies including biologics  
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as possible indicator of disease severity was 
similar in those studies [3, 5]. Analysis of response 
to secukinumab revealed that patients without a 
primary PASI 50 response to secukinumab did not 
achieve a good response to ixekizumab. This is in 
line with the results of a previous study with a 12-
week observation of a second IL17A-blocker. The 
longer patients were treated with secukinumab 
(probably owing to better efficacy) the better 
patients later responded to ixekizumab [5]. 
In summary, the overall response to ixekizumab as 
second IL17A blocker is relatively good. 
Neutralizing anti-drug antibodies to secukinumab 
appear not to be relevant as a possible 
explanation for treatment failure to secukinumab 
[9]. The better effect of ixekizumab might be at 
least partly explained by the fact that ixekizumab 
has shown a 50–100 times higher in-vitro affinity 
to IL17A compared to secukinumab [10, 11]. 
However, data about use of IL17A-blockers in 
reverse order are needed to support this 
explanation. We observed only a few adverse 
events in patients undergoing treatment with 
ixekizumab, none leading to discontinuation. 
Limitations of our study include the retrospective 
design and the comparably low number of 
included patients. 
 
Conclusion 
Our study results provide evidence that the use of 
ixekizumab as second IL17A-blocker is a 
reasonable therapeutic option in patients with at 
least a partial prior response to secukinumab. 
Further studies are needed to asses risk and 
benefit of employing a second IL17A-blocker after 
therapy failure of a first IL17A-blocker. 
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Figure 1. Distribution of 22 patients by response to ixekizumb following treatment to secukinumab. * SECU was stopped due 
to 2x prim nr joints, 1x sec nr joints and 2x AE. ** Therapy with ixekizumab was discontinued, Abbreviations: nr non-response, 
rp response, prim primary, sec secondary, IXE ixekizumab, SECU secukinumab. 
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